Conferences
Peptide Therapeutics Forum 2026
-
4-5 June 2026
-
Basel, Basel-Stadt, CH
The Peptide Therapeutics Forum 2026 will take place on June 4–5, 2026, at the Biozentrum in Basel. Over the last decade, the meeting has become one of the leading interdisciplinary conferences on bioactive peptides. Academic and industrial groups present state-of-the-art research, ranging from fundamental peptide science to pre-clinical and clinical drug candidates at all stages of development. The forum connects participants from universities, research institutes, global pharmaceutical industry, regulatory authorities, and CDMOs, offering a unique platform to exchange ideas, spark collaborations, and shape the future of peptide therapeutics.
Our posters
Other Resources
-
Our posters -
Other Resources
-
-
Development of an Automated Integrated Mass Spectrometry Platform for Qualitative and Quantitative Study of Peptide-Fc Fusion Protein
In this study, we established an integrated mass spectrometry platform for the comprehensive characterization of fusion proteindrugs, with various automation method applied in the immunocapture, SPE and data processing steps. For example,magnetic SPE (mSPE) beads can overcome the shortcomings of clogging and complicated operation associated with traditional SPE cartridges. Theymake the purification and concentration process simple, fast, and automation-compatible.Compared with traditional SPE,mSPEincreases efficiency by more than 30% and reduces costs by over 50%.
Get the PDF via email when it's ready. Leave your email address below.
WuXi AppTec requires your contact information to share our updates. Please review our privacy policy here. You can unsubscribe at any time.
-
Efficient Synthesis of Multi-14C-Labeled Fatty Acid-Modified Peptides
The success of GLP-1 receptor agonists has transformed metabolic disease therapy and accelerated peptide drug development across multiple fields. However, applying fatty acid-modified GLP-1 design principles to next-generation candidates often requires more sophisticated preclinical approaches.
Get the PDF via email when it's ready. Leave your email address below.
WuXi AppTec requires your contact information to share our updates. Please review our privacy policy here. You can unsubscribe at any time.
-
Evaluation of Time-Dependent Inhibition (TDI) of CYP3A4 by Peptide Therapeutics:A Comparison of Human Hepatocyte and Human Liver Microsome Assays
With the rapid expansion of peptide and peptidomimetic therapeutics, evaluating their Drug-Drug Interaction (DDI) potential has become an essential part of drug development. Cytochrome P450 3A4 (CYP3A4) inhibition is a primary driver of clinical DDIs. While traditional linear peptides are generally metabolized by proteases and pose low CYP-mediated DDI risks, modified and cyclic peptides may interactwith CYP enzymes. This study aims to evaluate the CYP3A4 (using Midazolam as a specific substrate) direct and time-dependent inhibition (TDI) potential of a diverse panel of peptide therapeutics.
Get the PDF via email when it's ready. Leave your email address below.
WuXi AppTec requires your contact information to share our updates. Please review our privacy policy here. You can unsubscribe at any time.
View More -
-
-
Optimizing Oral Formulation for Peptides and Novel Molecules: Breaking the Delivery Dilemma
ArticlesMay 28,2026
-
TidesID - Fast & Accurate Metabolite Identification for Peptides & Oligonucleotides 丨DMPK Frontiers
VideosMay 28,2026 -
Unlocking Peptide Receptor Radionuclide Therapies (PRRTs) and Diagnostic PRCs: What, Why, and Their Metabolic Studies
ArticlesMar 06,2026
-
Related Services and Platforms
Stay Connected
Keep up with the latest news and insights.
Submission successful!
We will send you an email with all the posters from this conference once they are ready. Thank you!
-
ok
